Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy

Nature Immunology

Volumn 16, Issue 8, 2015, Pages 850-858

  Barreira Da Silva, Rosa ^a,b   Laird, Melissa E ^a,b   Yatim, Nader ^a,b   Fiette, Laurence ^a,c   Ingersoll, Molly A ^a,b   Albert, Matthew L ^a,b  

^a INSTITUT PASTEUR   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON INDUCIBLE PROTEIN 10; SITAGLIPTIN; CHEMOKINE; CXCR3 PROTEIN, MOUSE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DPP4 PROTEIN, MOUSE; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; IN VIVO STUDY; LYMPHOCYTE; LYMPHOCYTE MIGRATION; LYMPHOCYTE TRAFFICKING; LYMPHOCYTE TRANSFER; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PROCESSING; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR REJECTION; ADOPTIVE TRANSFER; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL MOTION; DRUG EFFECTS; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; KNOCKOUT MOUSE; METABOLISM; NEOPLASMS, EXPERIMENTAL; PROCEDURES; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CXCL10; CHEMOKINES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; FLOW CYTOMETRY; IMMUNOTHERAPY; LYMPHOCYTES; MALE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; PYRAZINES; RECEPTORS, CXCR3; TRIAZOLES;

EID: 84937780190     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.3201     Document Type: Article

References (51)

1. Rot, A. & von Andrian, U.H. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol. 22, 891-928 (2004).
2. Weber, M. et al. Interstitial dendritic cell guidance by haptotactic chemokine gradients. Science 339, 328-332 (2013).
3. Mortier, A., Van Damme, J. & Proost, P. Overview of the mechanisms regulating chemokine activity and availability. Immunol. Lett. 145, 2-9 (2012).
4. Proost, P. et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 98, 3554-3561 (2001).
5. Bongers, J., Lambros, T., Ahmad, M. & Heimer, E.P. Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. Biochim. Biophys. Acta 1122, 147-153 (1992).
6. Durinx, C. et al. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur. J. Biochem. 267, 5608-5613 (2000).
7. Stecca, B.A. et al. Aberrant dipeptidyl peptidase IV (DPP IV/CD26) expression in human hepatocellular carcinoma. J. Hepatol. 27, 337-345 (1997).
8. Kajiyama, H. et al. Increased expression of dipeptidyl peptidase IV in human mesothelial cells by malignant ascites from ovarian carcinoma patients. Oncology 63, 158-165 (2002).
9. Karagiannis, T., Boura, P. & Tsapas, A. Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Ther. Adv. Drug Saf. 5, 138-146 (2014).
10. Lambeir, A.M. et al. Kinetic investigation of chemokine truncation by CD26/ dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J. Biol. Chem. 276, 29839-29845 (2001).
11. Casrouge, A. et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J. Clin. Invest. 121, 308-317 (2011).
12. Riva, A. et al. Truncated CXCL10 is associated with failure to achieve spontaneous clearance of acute hepatitis C infection. Hepatology 60, 487-496 (2014).
13. Ragab, D. et al. CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients. Cytokine 63, 105-112 (2013).
14. Christopherson, K.W. II, Cooper, S. & Broxmeyer, H.E. Cell surface peptidase CD26/ DPPIV mediates G-CSF mobilization of mouse progenitor cells. Blood 101, 4680-4686 (2003).
15. Oravecz, T. et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J. Exp. Med. 186, 1865-1872 (1997).
16. Fridman, W.H. et al. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res. 71, 5601-5605 (2011).
17. Pagès, F. et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29, 1093-1102 (2010).
18. Mortier, A., Gouwy, M., Van Damme, J. & Proost, P. Effect of posttranslational processing on the in vitro and in vivo activity of chemokines. Exp. Cell Res. 317, 642-654 (2011).
19. Groom, J.R. & Luster, A.D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol. Cell Biol. 89, 207-215 (2011).
20. Strieter, R.M., Kunkel, S.L., Arenberg, D.A., Burdick, M.D. & Polverini, P.J. Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem. Biophys. Res. Commun. 210, 51-57 (1995).
21. Christopherson, K.W. II, Hangoc, G., Mantel, C.R. & Broxmeyer, H.E. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 305, 1000-1003 (2004).
22. Forssmann, U. et al. Inhibition of CD26/dipeptidyl peptidase IV enhances CCL11/ eotaxin-mediated recruitment of eosinophils in vivo. J. Immunol. 181, 1120-1127 (2008).
23. Bonecchi, R. et al. Differential recognition and scavenging of native and truncated macrophage-derived chemokine (macrophage-derived chemokine/CC chemokine ligand 22) by the D6 decoy receptor. J. Immunol. 172, 4972-4976 (2004).
24. Loetscher, P. et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J. Biol. Chem. 276, 2986-2991 (2001).
25. Pashenkov, M. et al. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J. Clin. Oncol. 24, 5716-5724 (2006).
26. Krieg, A.M. CpG still rocks! Update on an accidental drug. Nucleic Acid Ther. 22, 77-89 (2012).
27. Overwijk, W.W. et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198, 569-580 (2003).
28. Budhu, S. et al. CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J. Exp. Med. 207, 223-235 (2010).
29. Gorrell, M.D. et al. Structure and function in dipeptidyl peptidase IV and related proteins. Adv. Exp. Med. Biol. 575, 45-54 (2006).
30. Wilson, M.J. et al. Elevation of dipeptidylpeptidase IV activities in the prostate peripheral zone and prostatic secretions of men with prostate cancer: possible prostate cancer disease marker. J. Urol. 174, 1124-1128 (2005).
31. Ou, X., O'Leary, H.A. & Broxmeyer, H.E. Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types. Blood 122, 161-169 (2013).
32. Antonsson, B., De Lys, P., Dechavanne, V., Chevalet, L. & Boschert, U. In vivo processing of CXCL12α/SDF-1α after intravenous and subcutaneous administration to mice. Proteomics 10, 4342-4351 (2010).
33. Favre-Kontula, L. et al. Quantitative detection of therapeutic proteins and their metabolites in serum using antibody-coupled ProteinChip arrays and SELDI-TOF-MS. J. Immunol. Methods 317, 152-162 (2006).
34. Carbone, A. et al. The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas/leukemias. Blood 86, 4617-4626 (1995).
35. Kacar, A. et al. Stromal expression of CD34, α-smooth muscle actin and CD26/ DPPIV in squamous cell carcinoma of the skin: a comparative immunohistochemical study. Pathol. Oncol. Res. 18, 25-31 (2012).
36. Adams, S. et al. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res. 64, 5471-5480 (2004).
37. Santos, A.M., Jung, J., Aziz, N., Kissil, J.L. & Pure, E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J. Clin. Invest. 119, 3613-3625 (2009).
38. Arwert, E.N. et al. Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation. Oncogene 31, 992-1000 (2012).
39. Lee, J., Fassnacht, M., Nair, S., Boczkowski, D. & Gilboa, E. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res. 65, 11156-11163 (2005).
40. Moelants, E.A., Mortier, A., Van Damme, J. & Proost, P. In vivo regulation of chemokine activity by post-translational modification. Immunol. Cell Biol. 91, 402-407 (2013).
41. Mortier, A. et al. Posttranslational modification of the NH2-terminal region of CXCL5 by proteases or peptidylarginine deiminases (PAD) differently affects its biological activity. J. Biol. Chem. 285, 29750-29759 (2010).
42. Ehlert, J.E., Gerdes, J., Flad, H.D. & Brandt, E. Novel C-terminally truncated isoforms of the CXC chemokine β-thromboglobulin and their impact on neutrophil functions. J. Immunol. 161, 4975-4982 (1998).
43. Van den Steen, P.E., Husson, S.J., Proost, P., Van Damme, J. & Opdenakker, G. Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase. Biochem. Biophys. Res. Commun. 310, 889-896 (2003).
44. Loos, T. et al. Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokines and new dimension of immunoregulation. Blood 112, 2648-2656 (2008).
45. Hodi, F.S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
46. Kerkar, S.P. & Restifo, N.P. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res. 72, 3125-3130 (2012).
47. Schmitt, T.M., Ragnarsson, G.B. & Greenberg, P.D. T cell receptor gene therapy for cancer. Hum. Gene Ther. 20, 1240-1248 (2009).
48. June, C.H. Adoptive T cell therapy for cancer in the clinic. J. Clin. Invest. 117, 1466-1476 (2007).
49. Gattinoni, L., Powell, D.J. Jr., Rosenberg, S.A. & Restifo, N.P. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6, 383-393 (2006).
50. Leach, D.R., Krummel, M.F. & Allison, J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734-1736 (1996).
51. Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 99, 12293-12297 (2002).